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Abstract
Background: The aim of the study was to evaluate the association of immunoglobulin G type of
autoantibodies to oxidized low-density lipoprotein (oxLDL-lgG) and oxLDL-lgM with the
progression of esophageal squamous cell carcinoma (ESSC).
Methods: Residents from Feicheng, China aged 40 to 69 years were screened for esophageal
lesions in a screening program conducted during the period of January 2008 to December 2006.
There were 33 controls with normal esophageal squamous epithelium cells, 37 patients with basal
cell hyperplasia, 47 with esophageal squamous cell dysplasia, and 43 with ESCC. All the participants
were diagnosed by biopsy and histopathological examination. Adiponectin, oxidized low-density
lipoprotein (oxLDL), autoantibodies against oxLDL (oxLDL-ab), OxLDL-lgG, and OxLDL-lgM
were determined by enzyme linked immunosorbent assay (ELISA). Total cholesterol, High-density
lipoprotein (HDL), triglyceride, serum albumin, and blood pressure were co-estimated. Analysis of
covariance for lipid levels was used to control the influence of covariates.
Results: The level of oxLDL-lgM increased gradually along with esophageal carcinoma progression.
The oxLDL-lgM levels in the ESCC group were the highest after possible covariates were
controlled. Binary logistic regression showed that oxLDL-lgM had a positive correlation with the
development of esophageal carcinoma, while oxLDL and oxLDL-ab had a negative correlation with
ESSC. No significant association between the levels of oxLDL-lgG and adiponectin and the different
stages of ESSC was observed.
Conclusion: The present study shows that the decreased oxLDL and oxLDL-ab and the elevated
oxLDL-lgM serum levels may relate to the development and progression of ESSC.
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Background
Conflicting data have been reported on the association
between low serum cholesterol levels and the risk for can-
cer mortality. Some observational studies show that low
serum cholesterol is associated with an increased risk of
cancer mortality [1-4], but some failed to establish a con-
nection [5-8].
A meta-analysis of 18 cohort studies showed a signifi-
cantly increased risk of total cancer death in men (but not
in women) with total cholesterol concentrations less than
160 mg/dL(4.15 mmol/L) compared with those with lev-
els at 160-199 mg/dL (4.15-5.16 mmol/L) [9].
There may be a causal link between low cholesterol and
cancer. But it is possible that the associations between low
blood cholesterol concentrations and risks of cancer are
the consequences of confounding factors [3,4]. In addi-
tion, it is also possible that the associations follow a
cause-and-effect relationship, possibly the preclinical can-
cer effect on cholesterol levels [10-12]. For instance, mor-
tality from liver and colon cancer is significantly
associated with a very low cholesterol level without any
evidence of a preclinical cholesterol-lowering effect [13].
Although the mechanism is unclear, this phenomenon
indicates that blood lipid levels are related to the develop-
ment and progression of tumors. However, expression
levels of serum cholesterol may not be the unique repre-
sentative of the lipid markers.
The significance of lipid and its novel constituents such as
adiponectin, immunoglobulin G and M types of autoan-
tibodies to oxidized low-density lipoprotein (oxLDL-lgG
and oxLDL-lgM) has been previously established in rela-
tion to cardiovascular disease [14,15]. Oxidized LDL, as
an autoantigen, plays a crucial role in atherogenic lesion
formation [16,17]. Serum oxLDL as well as the autoanti-
bodies against it (oxLDL-ab) may be considered as
biomarkers of lipid peroxidation [18]. There are two anti-
body isotypes to oxLDL, namely, the IgG and IgM autoan-
tibodies. Although still controversial, overall evidence
supports the notion that IgG autoantibodies to OxLDL are
associated with pro-atherogenic properties and IgM
autoantibodies to OxLDL with anti-atherogenic proper-
ties [19-21].
Meanwhile, studies also showed that adiponectin, oxLDL-
lgG, and oxLDL-lgM may play a role in various types of
malignancies [15]. Petridou, et al. studied the relationship
between adiponectin and childhood myeloblastic leuke-
mia [22], while Wang, et al. proposed that oxLDL autoan-
tibody might be related to esophageal cancer [23].
Furthermore, it has been found in animal models that a
high level of lipid peroxidation is closely associated with
carcinogenesis [24,25].
It can be assumed that lipid and its novel constitu-
ents(oxLDL-ab, oxLDL-lgG and oxLDL-lgM) may also be
associated with different stages in carcinogenesis proceed-
ing. Pathological and epidemiological studies suggest that
the malignant transformation of human esophageal
mucosa is a progressive process that starts from normal
epithelium to basal cell hyperplasia, followed by dyspla-
sia, or carcinoma in situ, and finally to invasive esopha-
geal squamous cell carcinoma (ESCC). Dysplasia, out of
the 4 progressive stages is considered as an important pre-
cancerous lesion of esophageal cancer [26-28].
In this context, we carried out a program for the screening
of esophageal lesions by endoscopic staining with 1.2%
iodine solution in Feicheng, China between January 2004
and December 2006. Through the program, we obtained
samples of 4 groups respectively having normal epithe-
lium, basal cell hyperplasia, dysplasia, or carcinoma in
situ, and ESCC. The foundation of these samples pressed
us to establish the relationship of the serum levels of lipid-
related constituents to these different lesions and carci-
noma of the esophagus, especially the levels of oxLDL-lgG
or/and oxLDL-lgM to the different stages in the progres-
sion of ESSC.
Methods
Study subjects
Between January 2004 and December 2006, we screened
all the residents aged 40 to 69 in Feicheng, China, who
agreed to participate in the program. We excluded those
with liver diseases, diabetes, or cardiovascular diseases
including coronary heart disease, angina pectoris, myocar-
dial infarction, cardiac arrhythmia, and heart failure diag-
nosed by general medical check up, electrocardiogram,
and abdomen supersonic inspection. All participants took
part in the endoscopic staining with 1.2% iodine solution.
Biopsies were taken from a non-staining area of the
mucosa, and the samples underwent two separate patho-
logic evaluations carried out by two pathologists. Based
on the examinations, the subjects were divided into four
groups: the control group with normal esophageal squa-
mous epithelium cells, the basal cell hyperplasia group,
the esophageal squamous cell dysplasia group, and the
ESCC group. The subjects in this study were randomly
selected from the four groups. There were 33 subjects with
normal esophageal squamous epithelium cells in the con-
trol group; 37 patients had basal cell hyperplasia, 47 had
esophageal squamous cell dysplasia, and 43 had ESCC.
Informed consent was obtained from all the subjects. The
study protocol was approved by the local ethics commit-
tee.Lipids in Health and Disease 2009, 8:48 http://www.lipidworld.com/content/8/1/48
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Measurements
An epidemiologic survey of the characteristics of the sub-
jects such as name, gender, age, and smoking and drink-
ing habits was conducted using a questionnaire. The body
weight and height of each subject were measured, and the
body mass index (BMI) was calculated as weight in kilo-
grams divided by height in square meters. Blood pressure
was measured by mercury sphygmomanometer. Hyper-
tension was defined as having systolic pressure (SBP) 
140 mmHg and/or diastolic pressure (DBP)  90 mmHg,
or those who were already undergoing medications for
hypertension.
Blood Sampling and Biochemical Analysis
Venous blood samples were taken in the morning after an
overnight fast of at least 12 hr. Plasma and serum were
separated according to the different requirements. The
specimens were kept frozen at -40°C until assayed. High
density lipoprotein (HDL), total cholesterol (TC), and
triglyceride (TG) levels were determined by enzymatic
techniques. Low density lipoprotein (LDL) was calculated
by the Friedewald formula [LDL = TC - HDL - TG/5].
Serum albumin was determined by the bromocresol green
method. All the assays were performed under the instruc-
tions supplied by the corresponding manufacturers.
Determination of serum ADP, oxLDL, oxLDL-ab, oxLDL-
lgG, and oxLDL-lgM
An enzyme-linked immunosorbent assay(ELISA) for ADP,
oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM was per-
formed with ADP, oxLDL, oxLDL-ab, oxLDL-lgG and
oxLDL-lgM ELISA kits purchased from ADL (Adliteram
Diagnostic Laboratories Inc., USA). According to the man-
ufacturer's instructions, using coated microtitration strips
96 wells, plasma was diluted 1:1 and incubated at room
temperature for 1 hr in plates precoated with ADP, oxLDL,
oxLDL-ab, oxLDL-lgG, or oxLDL-lgM, respectively. After
washing 3 times, the plates were incubated with horserad-
ish peroxidase (HRP) at room temperature for 30 min.
After the removal of unbound conjugates by washing 3
times, tetramethylbenzidine (TMB) was added to the
wells as a chromogenic substrate and incubated at room
temperature for 10 min in the dark. Color development
was stopped with stopping solution, and the absorbency
was measured at 450 nm within 30 min. ADP, oxLDL,
oxLDL-ab, oxLDL-lgG, or oxLDL-lgM titers were calcu-
lated by constructing a standard curve using the standards
included in the respective kits. The concentrations of ADP,
oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM in the sam-
ples were quantified in biomedical units as defined by the
manufacturer. The intra-assay and interassay reproduci-
bility (indicated by coefficients of variation) of the assay
were 6, 5, 7, 6, and 10 percent, respectively.
Statistical analysis
All statistical analyses were conducted using SPSS 15.0.
The baseline characteristics were presented for quantita-
tive data as mean (SD). The comparison in the four
groups was performed using the Student's t test. The qual-
itative data were tested by the Chi-square test. The correla-
tion between variables was tested using the Pearson
correlation test depending on the distribution of the data.
A general linear model analysis was used to control the
influence of covariates when comparing the concentra-
tions of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-
lgM among the four groups. Multinomial logistic regres-
sion was applied to analyze the influential factors. Proba-
bility was significant at a level of  0.05.
Results
Characteristics of subjects
The clinical and biochemical characteristics of the studied
population are shown in Table 1. The variables of age,
albumin, total cholesterol (TC), high-density lipoprotein
(HDL), low-density lipoprotein(LDL), oxLDL, oxLDL-ab,
oxLDL-lgG, and oxLDL-lgM were significantly different
among the four groups. There were no significant differ-
ences in the other variables.
Comparison of serum levels of ADP, oxLDL, oxLDL-ab, 
oxLDL-lgG, and oxLDL-lgM among the four groups
A general linear model analysis showed that there were
significant differences in the estimated marginal means of
plasma oxLDL and oxLDL-lgM among the four groups.
However, no significant differences were observed for
ADP, oxLDL-ab and oxLDL-lgG after controlling the con-
founding variables i.e. age, TC, HDL, LDL, and albumin
(Table 2). The results of the linear-by-linear association
analysis showed that the blood serum levels of oxLDL and
oxLDL-ab were decreased. However, the blood serum
level of oxLDL-lgM increased with the histological spec-
trum of disease from normal to early invasive squamous
cell carcinoma of the esophagus (Figure 1).
Association of ADP, oxLDL, oxLDL-ab, oxLDL-lgG, and 
oxLDL-lgM with multistage development of esophageal 
carcinoma
As shown in Table 3, the Odds ratio (OR) of ADP, oxLDL,
oxLDL-ab, oxLDL-lgG and oxLDL-lgM were associated
with the different stages in the development of esophageal
carcinoma (basal cell hyperplasia, dysplasia and early
invasive cancer) after adjusted for age, albumin, TC, HDL
and LDL.
It is also indicated that the ORs for oxLDL-lgM were posi-
tively linked with the ESSC and dysplasia group. However,
ORs for oxLDL and oxLDL-ab were negatively associated
with the two groups, even if the ORs did not reached sta-
tistics significantly levels in dysplasia group.Lipids in Health and Disease 2009, 8:48 http://www.lipidworld.com/content/8/1/48
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Discussion
In the present study, there was a significantly lower serum
level of TC and HDL-c. Moreover, there were significantly
higher serum levels of LDL-c in the ESSC group than those
in the control group, which is similar to those previously
found in the literature [1-5,10].
Plasma adiponectin levels were found to be lower in
patients with many cancers, especially in upper gastric
cancers, compared with those in the normal controls. It is
inversely correlated with tumor size, depth of invasion,
and tumor TNM stage, suggesting a potential role of adi-
ponectin in the progression of gastric cancer [29]. There
was no similar information for esophageal carcinoma. In
the present study, we did not find plasma adiponectin lev-
els to be related to the multistage development of esopha-
geal cancer.
The predominant isotype of oxLDL antibodies isolated
either from serum (free antibodies) or from precipitated
soluble immune complexes (antigen-associated antibod-
ies) is IgG, which is of the subclasses 1 and 3 [30,31]. A
positive correlation between the levels of oxLDL-lgG anti-
bodies and the different endpoints considered as evidence
Table 1: Characteristics of the Subjects
variables Control group Basal cell hyperplasia Dysplasia group ESSC group F/x2 p
Age, years 49 ± 8 53 ± 8 56 ± 7 58 ± 7 10.286 0.000*
Sex, M/F 18/15 24/13 28/19 28/15 1.155 0.764
Hypertension, Y/N 18/15 20/17 18/29 21/22 2.893 0.408
BMI, kg/m2 22.90 ± 2.72 22.93 ± 2.90 22.06 ± 2.60 21.73 ± 3.31 1.728 0.164
SBP, mmHg 132 ± 26 132 ± 19 131 ± 20 127 ± 17 0.549 0.649
DBP, mmHg 86 ± 14 85 ± 12 82 ± 12 78 ± 14 2.325 0.077
Smokers, Y/N 15/18 17/20 24/23 24/19 1.119 0.773
Drinkers, Y/N 15/18 24/13 24/23 23/20 2.890 0.409
Albumin, g/L 38 ± 3 44 ± 8 40 ± 6 38 ± 8 8.161 0.000*
TC, mmol/L 3.45 ± 1.09 3.63 ± 0.83 3.62 ± 0.80 2.54 ± 0.96 13.684 0.000*
TG, mmol/L 0.61 ± 0.43 0.68 ± 0.46 0.57 ± 0.40 0.50 ± 0.32 1.481 0.222
LDL, mmol/L 0.12 ± 0.33 0.08 ± 0.27 0.09 ± 0.28 0.23 ± 0.15 11.439 0.000*
HDL, mmol/L 0.77 ± 0.22 0.91 ± 0.22 0.85 ± 0.21 0.67 ± 0.24 8.667 0.000*
ADP, ng/L 10.27 ± 10.98 11.18 ± 13.10 14.33 ± 13.38 12.98 ± 11.79 0.850 0.469
oxLDL, ng/L 33.66 ± 11.54 27.40 ± 10.33 30.27 ± 11.83 23.94 ± 10.72 5.264 0.002*
oxLDL-ab, U/ml 38.33 ± 26.44 38.97 ± 21.38 32.52 ± 12.87 26.59 ± 7.88 4.210 0.007*
oxLDL-lgG, ng/ml 12.54 ± 4.67 18.14 ± 10.47 16.56 ± 8.42 10.23 ± 6.78 8.453 0.000*
oxLDL-lgM, ng/ml 20.56 ± 5.99 23.27 ± 6.17 24.63 ± 6.35 26.60 ± 5.88 6.402 0.000*
* p < 0.05; Abbreviations: ESSC, esophageal squamous cell carcinoma; MBI, body mass index; SBP, 0 systolic blood pressure; DBP, diastolic blood 
pressure; TC, total cholesterol; TG, triglyceride; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; ADP, adiponectin; oxLDL, oxidized 
low-density lipoprotein; oxLDL-lgG, immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein; oxLDL-lgM, immunoglobulin M 
type of autoantibodies to oxidized low-density lipoprotein.
Table 2: Estimated Marginal Means and UNIANOVA Test of Apinectin, oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM in Four 
Groupsa
ADP oxLDL oxLDL-ab oxLDL-lgG oxLDL-lgM
ESSC group 11.699 ± 2.715 25.436 ± 1.951 28.123 ± 3.124 13.378 ± 1.214 26.519 ± 1.073
Dysplasia group 13.980 ± 1.867 30.130 ± 1.675 32.101 ± 2.681 15.645 ± 1.065 24.380 ± 0.921
Basal cell hyperplasia group 11.903 ± 2.202 26.629 ± 1.976 37.367 ± 3.164 15.553 ± 1.257 22.989 ± 1.087
Control group 11.614 ± 2.363 32.790 ± 2.120 38.742 ± 3.395 12.656 ± 1.349 21.329 ± 1.166
F test 0.332 2.739 2.098 1.445 3.503
P 0.802 0.045 0.103 0.232 0.017
Trend testb 1.518 9.421 10.412 2.789 17.137
P 0.218 0.002 0.001 0.095 0.000
Abbreviations: TC, total cholesterol; TG, triglyceride; ADP, adiponectin; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; oxLDL, 
oxidized low-density lipoprotein; oxLDL-lgG, immunoglobulin G type of autoantibodies to oxidized low-density lipoprotein; oxLDL-lgM, 
immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein.
a Means (SE) for estimated marginal means; Covariates appearing in the model are evaluated at the following values: TG = 3.2961, LDL = 2.2317, 
HDL = 0.7992, Albumin = 40.2234, age = 54.55.
b Linear --by --linear association test.Lipids in Health and Disease 2009, 8:48 http://www.lipidworld.com/content/8/1/48
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of atherosclerotic vascular disease has been reported by
many studies [32,33]. In addition, the protective role of
IgM oxLDL antibodies has been proposed in human car-
diovascular diseases [25,34]. However, other studies have
failed to support these findings [35-37].
Recent research works show that the antibody against
oxLDL serum levels in patients with hepatocellular carci-
noma [38] and squamous cell carcinoma of the esopha-
gus [17] is lower than that in the normal controls.
However, the isotypes of oxLDL-lgG and oxLDL-lgM were
not separately detected in these reports.
The main finding of the present study is the descending
trends of plasma oxLDL, oxLDL-ab, and oxLDL-lgG levels
and the elevated trends of plasma oxLDL-lgM levels along
with the series of histological spectrum of disease from
normal to early invasive squamous cell carcinoma of the
esophagus.
In recent years, there has been a growing body of evidence
that states the excessive lipid peroxidation products
including oxLDL and anti-oxLDL autoantibodies, which
are reflected in the indicators of oxidative stress in vivo,
may play a key role in cancer development [39,40]. Lipid
Mean concentrations of serum biochemical indicators in group Figure 1
Mean concentrations of serum biochemical indicators in group. Mean concentrations of serum biochemical indicators 
in groups of ESSC (A), dysplasia (B), basal cell hyperplasia (C), and normal control (D). Adp, HDL, LDL, oxLDL, oxLDL-ab, 
oxLDL-IgG, oxLDL-IgM, TC, and TG respectively represent adiponectin, high-density lipoprotein, low-density lipoprotein, oxi-
dized low-density lipoprotein, total antibodies to oxidized low density lipoprotein, oxidized low-density lipoprotein IgG, oxi-
dized low-density lipoprotein IgM, total cholesterol, and total triglyceride.Lipids in Health and Disease 2009, 8:48 http://www.lipidworld.com/content/8/1/48
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peroxidation metabolites damage DNA and can seriously
inhibit DNA repair capacity through their direct interac-
tion with repair proteins [41]. Furthermore, they influ-
ence the intracellular redox equilibrium, affecting several
crucial signal transduction pathways [42]. The oxLDL,
shown either in vivo or in vitro, has a cytotoxic effect
against endothelial cells and smooth muscle cells of the
arterial wall, as well as a chemotactic activity for circulat-
ing monocytes [21]. Low serum levels of the oxLDL anti-
body can lead to uncontrolled cell proliferation and to the
reduction of apoptosis, contributing to the induction of
carcinogenesis. oxLDL increases the activity of C protein
kinase (PKC), which is a serin-treonin kinase that acts on
the cytoplasmatic transduction of the mytogenic signal,
induced from GF [43]. The PKC exerts its action support-
ing the activity of P21 ras protein involved in the patho-
genesis of many humans tumors [44]. oxLDL is also able
to induce the production and delivery of other growth fac-
tors (GF) such as that derived from platelets (PDGF),
probably through interleukin 1 and TNF-. It has been
demonstrated that PDGF, codified from c-sys oncogenes,
seems to be involved in the uncontrolled growth of many
tumors [45]. The anti-oxLDL autoantibodies may be acti-
vated through all these different ways to induce the devel-
opment and progression of esophageal cancer.
In this study, all subjects were diagnosed by histopathol-
ogy, which ruled out the possibility of the misclassifica-
tion error. In the experimental determination of the
indicators, we used less than 10 percent of the coefficient
of variation as quality control. In order to avoid the occur-
rence of collinearity, a covariance analysis was used in the
analysis. The variance inflation factor(VIF) of ADP,
oxLDL, oxLDL-ab, oxLDL-lgG, and oxLDL-lgM were
0.232, 0.880, 0.910, 0.867, and 0.984, respectively. There-
fore, the main results of this study were neither biased nor
by chance.
In the present study, we found that the descending levels
of oxLDL and oxLDL-ab may negatively related to the dif-
ferent stages of the development of esophageal cancer
while the elevated levels of oxLDL-lgM has a positive
potence, which is contrary in the case of their relations to
cardiovascular and cerebrovascular diseases revealed in
previous literature.
However, the isotype antibodies against oxLDL serum lev-
els in cancer cannot be defined in universal terms. Fur-
thermore, large clinical sample studies are required in
order to elucidate whether oxLDL as well as oxLDL anti-
bodies play a causative or merely consequential role in the
cancer process, and to designate a novel strategy for cancer
prevention and therapy.
Conclusion
This study shows that the decreasing oxLDL and oxLDL-ab
negatively relate to the different stages of the development
of esophageal squamous cell carcinoma while the ele-
vated oxLDL-lgM serum levels may positively relate to the
development and progression of ESSC. This conclusion
may be helpful for cancer prevention and therapy.
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